Search Results - "Malmestrom, C."

Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis by Axelsson, M., Malmeström, C., Nilsson, S., Haghighi, S., Rosengren, L., Lycke, J.

“…The major intermediate cytoskeletal protein of astrocytes, glial fibrillary acidic protein (GFAP), and that of axons, neurofilament light protein (NFL), may…”
Get full text

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis by Kuhle, J., Malmeström, C., Axelsson, M., Plattner, K., Yaldizli, Ö., Derfuss, T., Giovannoni, G., Kappos, L., Lycke, J.

“…Background Neurofilaments are promising biomarkers in multiple sclerosis (MS) and increased levels in cerebrospinal fluid (CSF) indicate axonal damage or…”
Get full text

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS by Novakova, L., Axelsson, M., Malmeström, C., Zetterberg, H., Blennow, K., Svenningsson, A., Lycke, J.

“…•All patients with ongoing disease activity (relapse or new lesions on MRI) had increased NFL or CXCL13.•The same proportion of patients with…”
Get full text

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs by Tedeholm, H, Lycke, J, Skoog, B, Lisovskaja, V, Hillert, J, Dahle, C, Fagius, J, Fredrikson, S, Landtblom, A-M, Malmeström, C, Martin, C, Piehl, F, Runmarker, B, Stawiarz, L, Vrethem, M, Nerman, O, Andersen, O

“…Background: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression…”
Get full text

The impact of hybrid immunity on immune responses after SARS‐CoV‐2 vaccination in persons with multiple sclerosis treated with disease‐modifying therapies by Rabenstein, Monika, Thomas, Olivia G., Carlin, Giorgia, Khademi, Mohsen, Högelin, Klara Asplund, Malmeström, Clas, Axelsson, Markus, Brandt, Anne Frandsen, Gafvelin, Guro, Grönlund, Hans, Kockum, Ingrid, Piehl, Fredrik, Lycke, Jan, Olsson, Tomas, Hessa, Tara

“…Background and purpose Hybrid immunity to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) develops from a combination of natural infection and…”
Get full text

Humoral and cellular immune responses after SARSCoV-2-Vaccination in a Swedish cohort of persons with multiple sclerosis treated with disease modifying therapies by Rabenstein, M., Thomas, O. G., Carlin, G., Hellström, Cecilia, Nilsson, Peter, Khademi, M., Hogelin, K. Asplund, Lycke, J., Malmestrom, C., Axelsson, M., Brandt, A. Frandsen, Gafvelin, G., Gronlund, H., Kockum, I., Piehl, F., Olsson, T., Hessa, T.

Get full text

Neurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic response by Novakova, L., Zetterberg, H., Axelsson, M., Sundström, P., Khademi, M., Gunnarsson, Martin, Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., Blennow, K., Lycke, J.

Get full text

Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis by Mattsson, N, Axelsson, M, Haghighi, S, Malmeström, C, Wu, G, Anckarsäter, R, Sankaranarayanan, S, Andreasson, U, Fredrikson, S, Gundersen, A, Johnsen, L, Fladby, T, Tarkowski, A, Trysberg, E, Wallin, A, Anckarsäter, H, Lycke, J, Andersen, O, Simon, AJ, Blennow, K, Zetterberg, H

“…Background Cell and animal experiments have shown that β-site APP-cleaving enzyme 1 (BACE1) may be involved in myelination. Objective Here, we assess the…”
Get full text

IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: Implications for their possible immunopathogenic roles by Malmeström, C., Andersson, B.A., Haghighi, S., Lycke, J.

“…Biological markers would provide valuable tools for tracking disease activity, immunopathological processes or therapeutic efficacy in MS. In this study we…”
Get full text

Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS by MALMESTROM, C, HAGHIGHI, S, ROSENGREN, L, ANDERSEN, O, LYCKE, J

“…To determine if CNS-derived proteins present in the CSF of multiple sclerosis (MS) patients reflect different pathologic processes of MS and if these proteins…”
Get full text

Serum neurofilament light for detecting disease activity in individual patients in multiple sclerosis: A 48-week prospective single-center study by Johnsson, M, Stenberg, YT, Farman, HH, Blennow, K, Zetterberg, H, Malmeström, C, Sandgren, S, Rosenstein, I, Lycke, J, Axelsson, M, Novakova, L

“…Background: Serum neurofilament light (sNfL) reflects neuroaxonal damage and is now used as an outcome in treatment trials of relapsing-remitting multiple…”
Get full text

Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis by Constantinescu, R., Krýsl, D., Bergquist, F., Andrén, K., Malmeström, C., Asztély, F., Axelsson, M., Menachem, E. B., Blennow, K., Rosengren, L., Zetterberg, H.

“…Background and purpose Clinical symptoms and long‐term outcome of autoimmune encephalitis are variable. Diagnosis requires multiple investigations, and…”
Get full text

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein by Novakova, Lenka, Zetterberg, Henrik, Sundström, Peter, Axelsson, Markus, Khademi, Mohsen, Gunnarsson, Martin, Malmeström, Clas, Svenningsson, Anders, Olsson, Tomas, Piehl, Fredrik, Blennow, Kaj, Lycke, Jan

“…To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) and the correlation between…”
Get full text

Inflammation-related plasma and CSF biomarkers for sclerosis by Huang, J, Khademi, M, Fugger, L, Lindhe, O, Novakova, L, Axelsson, M, Malmestrom, C, Constantinescu, C, Lycke, J, Piehl, F

Get full text

Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis by Novakova, Lenka, Axelsson, Markus, Malmeström, Clas, Zetterberg, Henrik, Björkhem, Ingemar, Karrenbauer, Virginija Danylaité, Lycke, Jan

“…Abstract Background Natalizumab therapy reduces inflammation and degeneration of the CNS in relapsing-remitting multiple sclerosis (RRMS). In cerebrospinal…”
Get full text

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients by Alping, Peter, Frisell, Thomas, Novakova, Lenka, Islam-Jakobsson, Protik, Salzer, Jonatan, Björck, Anna, Axelsson, Markus, Malmeström, Clas, Fink, Katharina, Lycke, Jan, Svenningsson, Anders, Piehl, Fredrik

“…Objective Many JC virus antibody‐positive relapsing–remitting multiple sclerosis (RRMS) patients who are stable on natalizumab switch to other therapies to…”
Get full text

Inflammation-related plasma and CSF biomarkers for multiple sclerosis by Huang, Jesse, Khademia, Mohsen, Fugger, Lars, Lindhe, Örjan, Novakova, Lenka, Axelsson, Markus, Malmeström, Clas, Constantinescu, Clara, Lycke, Jan, Piehl, Fredrik, Olsson, Tomas, Kockum, Ingrid

“…Effective biomarkers for multiple sclerosis diagnosis, assessment of prognosis, and treatment responses, in particular those measurable in blood, are largely…”
Get full text

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis by Novakova, Lenka, Axelsson, Markus, Khademi, Mohsen, Zetterberg, Henrik, Blennow, Kaj, Malmeström, Clas, Piehl, Fredrik, Olsson, Tomas, Lycke, Jan

“…Cerebrospinal fluid (CSF) biomarkers can reflect different aspects of the pathophysiology of relapsing‐remitting multiple sclerosis (RRMS). Understanding the…”
Get full text

Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis by Novakova, Lenka, Axelsson, Markus, Khademi, Mohsen, Zetterberg, Henrik, Blennow, Kaj, Malmeström, Clas, Piehl, Fredrik, Olsson, Tomas, Lycke, Jan

“…Background: The disease-modifying therapies (DMTs) in relapsing-remitting multiple sclerosis (RRMS) vary in their mode of action and when therapies are…”
Get full text

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab by Gunnarsson, Martin, Malmeström, Clas, Axelsson, Markus, Sundström, Peter, Dahle, Charlotte, Vrethem, Magnus, Olsson, Tomas, Piehl, Fredrik, Norgren, Niklas, Rosengren, Lars, Svenningsson, Anders, Lycke, Jan

“…Objective: The impact of present disease‐modifying treatments (DMTs) in multiple sclerosis (MS) on nerve injury and reactive astrogliosis is still unclear…”
Get full text